Empagliflozin and Rifampin Intravenous
Determining the interaction of Empagliflozin and Rifampin Intravenous and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration of empagliflozin with inducers of uridine diphosphate glucuronosyl transferase (UGT) enzymes may decrease the plasma concentrations and efficacy of empagliflozin, which is primarily metabolized in vitro by UGT1A3, 1A8, 1A9, and 2B7. The effect of UGT induction on empagliflozin has not been studied. MANAGEMENT: Coadministration of empagliflozin with UGT inducers should be avoided if possible. If concomitant use is required, dosage adjustments as well as increased clinical and laboratory monitoring should be considered whenever a UGT inducer is added to or withdrawn from empagliflozin therapy. References "Product Information. Glyxambi (empagliflozin-linagliptin)." Boehringer Ingelheim, Ridgefield, CT. "Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim, Ridgefield, CT. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 Cerner Multum, Inc. "Australian Product Information." O 0 View all 4 references
Professional:GENERALLY AVOID: Coadministration of empagliflozin with inducers of uridine diphosphate glucuronosyl transferase (UGT) enzymes may decrease the plasma concentrations and efficacy of empagliflozin, which is primarily metabolized in vitro by UGT1A3, 1A8, 1A9, and 2B7. The effect of UGT induction on empagliflozin has not been studied.
MANAGEMENT: Coadministration of empagliflozin with UGT inducers should be avoided if possible. If concomitant use is required, dosage adjustments as well as increased clinical and laboratory monitoring should be considered whenever a UGT inducer is added to or withdrawn from empagliflozin therapy.
- "Product Information. Glyxambi (empagliflozin-linagliptin)." Boehringer Ingelheim, Ridgefield, CT.
- "Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim, Ridgefield, CT.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
Generic Name: empagliflozin
Brand name: Jardiance
Synonyms: n.a.
Generic Name: rifampin
Brand name: Rifadin, Rifadin IV, Rimactane
Synonyms: Rifampin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Empagliflozin-Rifampin Oral, Intravenous
- Empagliflozin-Rifampin, Isoniazid, and Pyrazinamide
- Empagliflozin-Rifamycin
- Empagliflozin-Rifamycin Sodium
- Empagliflozin-Rifapentine
- Empagliflozin-Rifater
- Rifampin Intravenous-Empagliflozin and linagliptin
- Rifampin Intravenous-Empagliflozin and metformin
- Rifampin Intravenous-Empagliflozin and Metformin Extended-Release Tablets
- Rifampin Intravenous-Empagliflozin and Metformin Tablets
- Rifampin Intravenous-Empliciti
- Rifampin Intravenous-Emsam